PMID: 42383207

Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.

Malhotra Atul, Gottlieb Daniel J, Kundel Vaishnavi, Woehrle Holger, Chakladar Sujatro, Firmino Goncalves Livia, Calamai Giulia

Contemporary clinical trials communications · 2026

Vol. 52, pp. 101660

View on PubMedDOI

This entry links to third-party literature. For research use only.

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.